Sign in
Taking peopleNo phase

Integration of Stepped Care for Perinatal Mood and Anxiety Disorders Among Women Attending MCH Clinics

Key facts

Who runs it
Kenyatta National Hospital
Where
Kenya2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
2,970 people, planned
Started
17 Feb 2025
Expected to end
Mar 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)
Record updated
10 December 2025

Who can take part

Age
14 years and older
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Pregnant and ≥28 weeks gestation
  • Attending ANC care at the facility
  • ≥14 years old
  • Screen positive for PMAD symptoms (PHQ-2≥3 and/or GAD-2≥3)
  • Willing to return to the MCH and PMTCT clinic for study visits

Who cannot take part

  • Less than 28 weeks gestation
  • Any woman at high risk of self-harm based on a study self-harm assessment protocol,
  • Has cognitive impairments or psychotic symptoms

This trial is currently available in Kenya.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Perinatal mood and anxiety disorders (PMAD), defined as depression and anxiety during pregnancy or up to 1 year postpartum, account for substantial morbidity and mortality among birthing people globally especially in low- and middle-income countries. Several evidence-based interventions are recommended for identification and management of PMAD by non-specialist providers in resource-limited settings. This cluster-randomized trial seeks to evaluate the effect of a stepped-care intervention for screening and treatment of PMAD among perinatal women, on clinical and implementation outcomes.

The 2 groups in the trial

  • Control arm: Enhanced Standard of careNo study treatment, for comparison

    Control facilities will provide enhanced standard of care. The enhanced standard of care will include two enhancements: 1. HIV Testing Services (HTS) providers and lay workers will conduct screening for perinatal mood and anxiety disorders (PMAD) using the PHQ-2 and GAD-2. 2. The study team will provide a PMAD referral information sheet to all control facilities describing inpatient and outpatient psychiatry services at the nearby referral hospitals

  • Intervention arm: Integrated Perinatal Mental Health Program (IPMH)Treatment being tested

    Intervention facilities will receive the Integrated Perinatal Mental Health Program (IPMH). This includes: 1. Systematic screening for PMAD symptoms using PHQ-2 and GAD-2. Positive screeners (PHQ-2≥3 and/or GAD-2≥3) will then be referred to nurses to administer additional screening by PHQ-9 and GAD-7 2. Non-specialist delivery of PM+ for participants with likely depression (PHQ-9≥10) or anxiety (GAD-7≥10) delivered weekly 3. In-facility tele-linkage to mental health specialist for participants with severe depressive symptoms (PHQ-9≥15), those who endorse suicidality, or non-responders to Problem Management+

    Treatment: Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
10 December 2025